达维塔

最新新闻

• Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $250
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  TD Cowen Upgrades DaVita(DVA.US) to Buy Rating, Raises Target Price to $220
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Announces Target Price $215
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  TD Cowen Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $201
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 公司公告
  DaVita | 4: Statement of changes in beneficial ownership of securities-Director Moore Gregory J.
  SEC · 2026/5/19
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Hinge Health, Inc. Class A (HNGE) and DaVita (DVA)
  TipRanks · 2026/8/5
• 公司公告
  DaVita | 4: Statement of changes in beneficial ownership of securities-Director Hollar Jason M.
  SEC · 2026/3/18
• 评级变动
  Deutsche Bank Maintains DaVita(DVA.US) With Buy Rating, Raises Target Price to $265
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Barclays Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $224
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• At US$180, Is DaVita Inc. (NYSE:DVA) Worth Looking At Closely?
  Simply Wall St · 2026/8/27
• 评级变动
  TD Cowen Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $201
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $215
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 公司公告
  DaVita | 4: Statement of changes in beneficial ownership of securities-Director Moore Gregory J.
  SEC · 2025/11/18
• 公司公告
  DaVita | 4: Statement of changes in beneficial ownership of securities-Director Hollar Jason M.
  SEC · 2026/5/19
• 评级变动
  Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Announces Target Price $205
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Truist Financial Maintains DaVita(DVA.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Daon Shares (002838): Consolidation synergies drive a sharp earnings surge; DVA commercialization enters the realization phase.
  Changjiang Securities · 2026/8/31
• UBS Maintains DaVita(DVA.US) With Buy Rating, Raises Target Price to $270
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• 评级变动
  BofA Securities Maintains DaVita(DVA.US) With Sell Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 公司公告
  DaVita | 4: Statement of changes in beneficial ownership of securities-Director Moore Gregory J.
  SEC · 2026/3/18

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。